CGEM shows severe cash burn acceleration with R&D expenses surging 31% while stockholders' equity collapsed 31% and operating cash flow deteriorated 21%.
The company is burning through cash at an unsustainable rate with operating cash flow worsening to -$176M and net losses deepening to -$220M, raising serious questions about runway duration. The 31% decline in stockholders' equity to $409M combined with accelerating R&D spend suggests the company may need to raise capital soon or face funding constraints that could jeopardize clinical programs.
CGEM's financials show a company in distress with R&D expenses surging 31% to $187M while operating losses widened to -$242M and net losses deepened 31% to -$220M. The balance sheet deteriorated significantly with stockholders' equity falling 31% to $409M and total assets declining 28% to $448M, while liabilities increased 26%. Operating cash burn worsened 21% to -$176M, creating a dangerous trajectory that threatens the company's ability to fund its clinical pipeline without immediate capital infusion.
Net income declined 31.4% — review whether driven by operations, interest costs, or non-recurring items.
R&D investment increased 31.1% — signals commitment to future product development, though near-term margin impact.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Total assets contracted 27.9% — asset sales, write-downs, or balance sheet optimization underway.
Liabilities increased 25.9% — monitor debt-to-equity ratio and interest coverage.
Current liabilities rose 23.1% — increased short-term obligations, watch current ratio.
Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →